Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies (Q37933157)

25 August 2017

1 reference

title

Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies (English)

1 reference

25 August 2017

liver transplantation

1 reference

inferred from title

hepatocellular carcinoma

1 reference

Yasunobu Matsuda

1

1 reference

25 August 2017

Takafumi Ichida

series ordinal

2

1 reference

25 August 2017

Manabu Fukumoto

series ordinal

3

1 reference

25 August 2017

language of work or name

1 reference

16 September 2011

1 reference

Medical Molecular Morphology

25 August 2017

1 reference

25 August 2017

44

1 reference

25 August 2017

3

1 reference

25 August 2017

117-124

1 reference

https://scigraph.springernature.com/pub.10.1007/s00795-011-0547-2

25 August 2017

0 references

cites work

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Clinically relevant radioresistant cells efficiently repair DNA double-strand breaks induced by X-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Raf meets Ras: completing the framework of a signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Complete response for advanced liver cancer during sorafenib therapy: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Resection and liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

mTOR inhibitors for hepatocellular cancer: a forward-moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00795-011-0547-2

Alpha-particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis.

21 January 2018

1 reference

12 December 2020

Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan

1 reference

12 December 2020

Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization

1 reference

12 December 2020

Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis

1 reference

12 December 2020

Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report

1 reference

12 December 2020

Sirolimus: a potent new immunosuppressant for liver transplantation

1 reference

12 December 2020

Overexpressed Id-1 is associated with a high risk of hepatocellular carcinoma development in patients with cirrhosis without transcriptional repression of p16

1 reference

12 December 2020

Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.

1 reference

12 December 2020

10.1007/S00795-011-0547-2

Identifiers

DOI

1 reference

25 August 2017

1 reference